Evidence map›Paper›PMID 35157784›Full record

ArticleClinical pharmacology in drug development2022

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.

Hendrik-Tobias Arkenau, Donatienne Taylor, Xiaoying Xu, Shripad Chitnis, Casilda Llacer-Perez, Kathleen Moore, Prasanna Kumar Nidamarthy, Palanichamy Ilankumaran, Judith De Vos-Geelen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Hendrik-Tobias ArkenauSarah Cannon Research Institute, London, UK.
Donatienne TaylorCHU UCL Namur, Site Sainte-Elisabeth, Namur, Belgium.
Xiaoying XuNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Shripad ChitnisNovartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
Casilda Llacer-PerezHospital Clinico Universitario Virgen de la Victoria, Malaga, Spain.
Kathleen MooreStephenson Cancer Centre, University of Oklahoma, Oklahoma City, Oklahoma, USA.
Prasanna Kumar NidamarthyNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Palanichamy IlankumaranNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Judith De Vos-GeelenDepartment of Internal Medicine, Division of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, The Netherlands.
Novartis (United States) · USCRUK Lung Cancer Centre of Excellence · GBHospital Clínico Universitario Virgen de la Victoria · ESJanssen (United States) · USMaastro Clinic · NLNovartis (India) · INOklahoma State University Oklahoma City · USUniversity of Namur · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 postapproval study assessed the effect of the mitogen-activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined oral contraceptives (COCs) containing norethindrone (NE; 1 mg daily) and ethinyl estradiol (EE; 0.035 mg daily) in 19 female patients with solid tumors. Compared with NE/EE administered without trametinib, NE/EE administered with steady-state trametinib was associated with a clinically nonrelevant 20% increase in NE exposure (area under the curve [AUC]) and no effect on EE exposure (geometric mean ratio [geo-mean] of NE/EE + trametinib to NE/EE [90%CI]: NE AUC calculated to the end of a dosing interval at steady-state [AUC

Indexed as

NeoplasmsNorethindroneContraceptives, Oral, CombinedEthinyl EstradiolFemaleHumansPyridonesPyrimidinonesContraceptives, Oral, CombinedEthinyl EstradiolNorethindronePyridonesPyrimidinonestrametinibanaplastic thyroid cancerMEK inhibitormelanomanon-small-cell lung canceroral contraceptiontrametinib

Identifiers

PMID35157784
PMCPMC9304124
OpenAlexW4212982480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.